AstraZeneca (AZN) Stock News

AstraZeneca and Daiichi Sankyo reported promising results for DATROWAY (datopotamab deruxtecan) in treating non-small cell lung cancer (NSCLC) across three clinical trials presented at ASCO 2025. In TROPION-Lung02, the combination of DATROWAY with pembrolizumab showed a 54.8% objective response rate in the doublet arm and 55.6% in the triplet arm including chemotherapy. TROPION-Lung04 demonstrated a 57.5% response rate when combining DATROWAY with rilvegostomig. The NeoCOAST-2 trial showed encouraging results in early-stage NSCLC with a 35.2% pathologic complete response rate when combining DATROWAY with durvalumab and chemotherapy. Safety profiles were consistent with previous studies, with manageable adverse events including some cases of interstitial lung disease.

AstraZeneca's IMFINZI (durvalumab) in combination with FLOT chemotherapy demonstrated significant success in treating early-stage gastric and gastroesophageal junction cancers in the MATTERHORN Phase III trial. The perioperative treatment showed a 29% reduction in disease progression, recurrence, or death risk compared to chemotherapy alone. At two years, 67.4% of IMFINZI-treated patients remained event-free versus 58.5% in the comparator arm. The trial also showed a strong trend toward improved overall survival (HR=0.78). The IMFINZI-based regimen more than doubled the pathologic complete response rate (19% vs 7%). The safety profile was consistent with known profiles, with similar Grade 3 or higher adverse events between arms. This marks IMFINZI as the first and only immunotherapy to show statistically significant event-free survival in a global Phase III trial for this indication.

AstraZeneca's SERENA-6 Phase III trial demonstrated significant success for camizestrant in treating HR-positive breast cancer. The drug, combined with CDK4/6 inhibitors, reduced disease progression or death risk by 56% compared to standard treatment, with median progression-free survival of 16.0 months versus 9.2 months. The trial marked the first use of circulating tumor DNA monitoring to detect and treat emerging resistance before disease progression. Camizestrant also improved quality of life metrics, delaying deterioration by 23.0 months compared to 6.4 months with standard treatment. The safety profile was consistent with known profiles, though Grade 3 adverse events were higher in the camizestrant arm (60% vs 46%). Based on these results, the FDA granted Breakthrough Therapy Designation for camizestrant in combination with CDK4/6 inhibitors for HR-positive, HER2-negative advanced breast cancer patients with ESR1 mutations.

AstraZeneca and Daiichi Sankyo's ENHERTU demonstrated superior efficacy in the DESTINY-Gastric04 phase 3 trial for second-line HER2-positive gastric cancer treatment. The drug showed a 30% reduction in death risk compared to ramucirumab plus paclitaxel, with median overall survival of 14.7 vs 11.4 months. ENHERTU achieved significant improvements across key metrics: 26% reduction in disease progression risk, 44.3% objective response rate (vs 29.1%), and 7.4 months median duration of response (vs 5.3 months). The safety profile remained consistent with previous trials, though interstitial lung disease occurred in 13.9% of ENHERTU patients, mostly low-grade. These results position ENHERTU as a potential global standard of care for second-line treatment in HER2-positive gastric cancer patients.

Danaher (NYSE: DHR) has announced a strategic partnership with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and commercialize advanced diagnostic tools for precision medicine. The collaboration will leverage Danaher's Centers for Enabling Precision Medicine and technology from its subsidiary, Leica Biosystems, focusing initially on digital and computational pathology products with AI-assisted algorithms.

The partnership aims to create diagnostic tests that help identify patients most likely to benefit from targeted therapies. Leica Biosystems will utilize its global laboratory network to deploy these tests worldwide, supported by its commitment to open-access DICOM standards for enhanced workflow connectivity.

AstraZeneca will present significant clinical trial data at the 2025 ASCO Annual Meeting (May 30-June 3), marking its seventh consecutive year with plenary presentations. The company will showcase over 80 abstracts featuring 20 medicines, including two plenary presentations. Key highlights include the SERENA-6 Phase III trial of camizestrant for HR-positive breast cancer, MATTERHORN Phase III trial of IMFINZI for gastric cancer, and DESTINY-Breast09 Phase III trial of ENHERTU for HER2-positive metastatic breast cancer. The SERENA-6 trial is notably the first positive Phase III trial for a next-generation oral SERD in first-line setting, while DESTINY-Breast09 is the first trial in over a decade showing superiority over first-line standard care in HER2-positive metastatic patients.

AstraZeneca's AIRSUPRA demonstrated exceptional results in the Phase IIIb BATURA trial for mild asthma treatment. The study showed a 47% reduction in severe exacerbation risk compared to albuterol alone (5.1% vs 9.1%, p0.001). The trial was stopped early due to overwhelming efficacy. Key findings include a in systemic corticosteroid exposure and consistent safety profile with albuterol. AIRSUPRA is the first FDA-approved anti-inflammatory rescue medication for as-needed treatment in asthma patients 18 and older. The results, published in the New England Journal of Medicine and presented at ATS 2025, support AIRSUPRA as a potential new standard of care, particularly significant for mild asthma patients who represent 50-70% of cases and account for up to 30% of asthma-related exacerbations and deaths.

AstraZeneca (AZN) will present over 75 abstracts, including 8 late-breakers, at the American Thoracic Society (ATS) International Conference from May 16-21, 2025. The presentations focus on their respiratory portfolio targeting asthma, COPD, and other inflammatory diseases. Key highlights include:

- AIRSUPRA data showing potential as preferred rescue treatment across all asthma severities

- BREZTRI studies demonstrating impact on cardiopulmonary outcomes in COPD patients

- FASENRA research in EGPA treatment and eosinophilic inflammation

- TEZSPIRE data on severe asthma and chronic rhinosinusitis

- Early-stage pipeline developments including AI/machine learning applications in respiratory disease research

The company aims to transform respiratory care, addressing COPD as the third leading cause of death worldwide and targeting unmet needs in asthma treatment.

AstraZeneca's IMFINZI® (durvalumab) demonstrated significant success in a Phase III POTOMAC trial for treating high-risk non-muscle-invasive bladder cancer (NMIBC). The study showed that one year of IMFINZI treatment combined with standard BCG therapy significantly improved disease-free survival (DFS) compared to BCG therapy alone. This is particularly significant as over 70% of bladder cancer patients are diagnosed with NMIBC, and about half are classified as high-risk. Currently, 80% of patients experience disease recurrence, with almost half potentially requiring bladder removal surgery. The safety profile was consistent with known data, and the addition of IMFINZI did not compromise BCG therapy completion. However, a second experimental arm testing IMFINZI plus BCG induction-only therapy did not meet the DFS endpoint.